N-truncated amyloid beta (Aβ) peptide Alzheimer's disease immunotherapy Immunodominant epitope N-truncated and N-modified forms of amyloid beta (Aβ) peptide are found in diffused and dense core plaques in Alzheimer's disease (AD) and Down's syndrome patients as well as transgenic mouse models of AD. Although the pathological significance of these shortened forms Aβ is not completely understood, previous studies have demonstrated that these peptides are significantly more resistant to degradation, aggregate more rapidly in vitro and exhibit similar or, in some cases, increased toxicity in hippocampal neuronal cultures compared to the full length peptides. In the present study we further investigated the mechanisms of toxicity of one of the most abundant N-truncated/modified Aβ peptide bearing aminoterminal pyroglutamate at position 3 (AβN3(pE)). We demonstrated that AβN3(pE) oligomers induce phosphatidyl serine externalization and membrane damage in SH-SY5Y cells. Also, we produced AβN3(pE)-specific polyclonal antibodies in rabbit and identified an immunodominant epitope recognized by anti-AβN3 (pE) antibodies. Our results are important for developing new immunotherapeutic compounds specifically targeting AβN3(pE) aggregates since the most commonly used immunogens in the majority of vaccines for AD have been shown to induce antibodies that recognize the N-terminal immunodominant epitope (EFRH) of the full length Aβ, which is absent in N-amino truncated peptides.
Introduction
The accumulation of fibrillar and oligomeric forms of amyloid-beta (Aβ) peptide in the brain has been hypothesized to play a central role in the neuropathology of Alzheimer's disease (AD) (Masters et al., 1985; Hardy and Selkoe, 2002; Walsh and Selkoe, 2004; Haass and Selkoe, 2007) . The main Aβ variants detected in the human brain are Aβ1-40 and Aβ1-42, however a significant proportion of AD brain Aβ consists also of N-terminal truncated/modified species (Mori et al., 1992; Seubert et al., 1992; Saido et al., 1995 Saido et al., , 1996 Kuo et al., 1997; Tekirian et al., 1998; Russo et al., 2001; Miravalle et al., 2005) . Although the pathological significance of N-terminally truncated/ modified forms of Aβ is not completely understood, previous studies have demonstrated that these shortened Aβ forms are significantly more resistant to degradation, aggregate more rapidly in vitro and exhibit similar or, in some cases, increased toxicity in hippocampal neuronal cultures compared to the full length peptides (Pike et al., 1995; Kuo et al., 1997; Russo et al., 2002) . Furthermore, N-truncated Aβ peptides progressively accumulate in the brain of sporadic AD patients, in early onset Familial Alzheimer's disease (FAD) patients and in Down syndrome brain (Naslund et al., 1994; Saido et al., 1995; Tekirian et al., 1998; Huse et al., 2002; Kalback et al., 2002; Piccini et al., 2005; Vanderstichele et al., 2005; Guntert et al., 2006; Liu et al., 2006) . In a recent study, Sergeant et al. (2003) showed that Aβ amino truncated peptides aggregate at the earliest stages of AD even before the appearance of clinical symptoms . Moreover, diffuse non-fibrillar pre-amyloid aggregates contain N-truncated Aβ, which might play an essential role in neuronal loss and cognitive decline in AD patients (Kumar-Singh et al., 2000) . Finally, the presence of intraneuronal pool of N-truncated Aβ peptides has been shown to correlate with the progression of pathology and neuronal loss in a transgenic mouse model APP/PS1KI, described earlier (Casas et al., 2004; Wirths et al., 2007; Bayer et al., 2008) . Thus, the N-terminally truncated/modified Aβ peptides represent highly desirable and abundant therapeutic targets.
Anti-Aβ immunotherapy has been shown to disrupt Aβ aggregates, block aggregation, attenuate toxicity, as well as promote the clearance of the peptide in the central nervous system (CNS). Immunotherapy approaches, both active immunization with Aβ peptide, or passive transfer of anti-Aβ antibodies, have shown therapeutic efficacy in several amyloid precursor protein transgenic (APP/Tg) mouse models, which develop AD-like amyloid plaque pathology (Schenk et al., 1999; Bard et al., 2000; Town et al., 2001; Brody and Holtzman, 2008) , as well as canine and primate models of amyloidosis (Lemere et al., 2004; Head et al., 2008) . Interestingly, the majority of the previous E-mail address: gokar@servidor.unam.mx (G. Gevorkian).
